摘要
目的探讨齐拉西酮与阿立哌唑治疗首发精神分裂症的临床疗效及对代谢的影响。方法将118例首发精神分裂症患者随机分为齐拉西酮组与阿立哌唑组,2组患者分别接受齐拉西酮及阿立哌唑口服,疗程8周。比较2组治疗前后阳性与阴性症状量表(PANSS)、不良反应发生率及对代谢的影响。结果治疗后2组PANSS量表分均显著下降(P<0.05),但2组间无显著差别(P>0.05);齐拉西酮组与阿立哌唑组不良反应发生率分别为40.0%和44.8%,差别无统计学意义(P>0.05);2组治疗后血脂、体重指数及空腹血糖均无显著改变(P>0.05)。结论齐拉西酮与阿立哌唑治疗首发精神分裂症均可获得理想疗效,且安全性好,对代谢糖脂无显著影响。
Objective To explore the effect of ziprasidone and aripiprazole on first-episode schizophrenia and the influence of them on the metabolism. Methods 118 cases with first-episode schizophrenia were randomly divided into ziprasidone group and aripiprazole group. The two groups received ziprasidone and aripiprazole treatment respectively. The course of treatment was 8 weeks. PANSS, the occurrence of adverse rate and the effect for metabolism were analyzed. Results PANSS scores greatly decreased after treatment in two groups （P〈0.05）, while there were no significant difference between two groups （P 〈0.05） ; The adverse rates of ziprasidone group and aripiprazole group were 40.0% and 44.8G respectively, and there was no significant difference between two groups （P〈0.05） There were no significant difference for blood lipid, BMI and fasting blood-glucose before and after treatment in both groups （P〈0.05）. Conclusion Ziprasidone and aripiprazole have ideal effect on first-episode schizophrenia with good safety and have no significant effect on the metabolism.
出处
《中国实用神经疾病杂志》
2014年第1期57-58,共2页
Chinese Journal of Practical Nervous Diseases
